{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:56:42Z","timestamp":1790996202038,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40120-024-00580-2","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T07:03:07Z","timestamp":1706770987000},"page":"389-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Conversion to Brivaracetam Monotherapy in Clinical Practice: A Retrospective Study"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-0083","authenticated-orcid":false,"given":"Simona","family":"Lattanzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Martellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Audenino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Boero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Ferlazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Chiesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Dainese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Piccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Labate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"580_CR1","first-page":"1","volume":"10","author":"P Klein","year":"2018","unstructured":"Klein P, Diaz A, Gasalla T, Whitesides J. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol. 2018;10:1\u201322.","journal-title":"Clin Pharmacol"},{"key":"580_CR2","unstructured":"Brivaracetam. Highlight of prescribing information. https:\/\/www.briviact.com\/briviact-PI.pdf. Accessed Oct 2023."},{"key":"580_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106327","volume":"163","author":"BD Moseley","year":"2020","unstructured":"Moseley BD, Chanteux H, Nicolas JM, Laloyaux C, Gidal B, Stockis A. A review of the drug-drug interactions of the antiepileptic drug brivaracetam. Epilepsy Res. 2020;163: 106327.","journal-title":"Epilepsy Res"},{"key":"580_CR4","unstructured":"EMA. Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-3_en.pdf. Accessed Oct 2023."},{"key":"580_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.seizure.2015.03.003","volume":"27","author":"S Lattanzi","year":"2015","unstructured":"Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Lacosamide monotherapy for partial onset seizures. Seizure. 2015;27:71\u20134.","journal-title":"Seizure"},{"key":"580_CR6","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","volume":"58","author":"RS Fisher","year":"2017","unstructured":"Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:522\u201330.","journal-title":"Epilepsia"},{"key":"580_CR7","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1111\/epi.17223","volume":"63","author":"S Lattanzi","year":"2022","unstructured":"Lattanzi S, Ascoli M, Canafoglia L, et al. Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures. Epilepsia. 2022;63:e42\u201350.","journal-title":"Epilepsia"},{"key":"580_CR8","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1111\/epi.17740","volume":"64","author":"S Lattanzi","year":"2023","unstructured":"Lattanzi S, Canafoglia L, Canevini MP, et al. Adjunctive brivaracetam and sustained seizure frequency reduction in very active focal epilepsy. Epilepsia. 2023;64:2922\u201333.","journal-title":"Epilepsia"},{"key":"580_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573\u20137.","journal-title":"Ann Intern Med"},{"key":"580_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.seizure.2018.07.017","volume":"61","author":"M Hirsch","year":"2018","unstructured":"Hirsch M, Hintz M, Specht A, Schulze-Bonhage A. Tolerability, efficacy and retention rate of brivaracetam in patients previously treated with levetiracetam: a monocenter retrospective outcome analysis. Seizure. 2018;61:98\u2013103.","journal-title":"Seizure"},{"key":"580_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","volume":"52","author":"SL Yates","year":"2015","unstructured":"Yates SL, Fakhoury T, Liang W, Eckhardt K, Borghs S, D\u2019Souza J. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52:165\u20138.","journal-title":"Epilepsy Behav"},{"key":"580_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107939","volume":"118","author":"BJ Steinhoff","year":"2021","unstructured":"Steinhoff BJ, Klein P, Klitgaard H, et al. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review. Epilepsy Behav. 2021;118: 107939.","journal-title":"Epilepsy Behav"},{"key":"580_CR13","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1212\/WNL.0000000000002545","volume":"86","author":"S Lattanzi","year":"2016","unstructured":"Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis. Neurology. 2016;86:1344\u201352.","journal-title":"Neurology"},{"key":"580_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","volume":"82","author":"S Lattanzi","year":"2022","unstructured":"Lattanzi S, Trinka E, Zaccara G, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs. 2022;82:199\u2013218.","journal-title":"Drugs"},{"key":"580_CR15","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s40263-021-00856-3","volume":"35","author":"S Lattanzi","year":"2021","unstructured":"Lattanzi S, Canafoglia L, Canevini MP, et al. Adjunctive brivaracetam in focal epilepsy: real-world evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST). CNS Drugs. 2021;35:1289\u2013301.","journal-title":"CNS Drugs"},{"key":"580_CR16","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s40120-022-00402-3","volume":"11","author":"S Lattanzi","year":"2022","unstructured":"Lattanzi S, Canafoglia L, Canevini MP, et al. Brivaracetam as early add-on treatment in patients with focal seizures: a retrospective, multicenter. Real-World Study Neurol Ther. 2022;11:1789\u2013804.","journal-title":"Neurol Ther"},{"key":"580_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/ane.13059","volume":"139","author":"V Villanueva","year":"2019","unstructured":"Villanueva V, L\u00f3pez-Gonz\u00e1lez FJ, Mauri JA, et al. BRIVA-LIFE\u2014a multicenter retrospective study of the long-term use of brivaracetam in clinical practice. Acta Neurol Scand. 2019;139:360\u20138.","journal-title":"Acta Neurol Scand"},{"key":"580_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.eplepsyres.2018.02.005","volume":"141","author":"S Arnold","year":"2018","unstructured":"Arnold S, Badalamenti V, Diaz A, et al. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: two double-blind, randomized, multicenter, historical control, phase\u00a0III studies. Epilepsy Res. 2018;141:73\u201382.","journal-title":"Epilepsy Res"},{"key":"580_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40263-023-01033-4","volume":"37","author":"V Villanueva","year":"2023","unstructured":"Villanueva V, Laloyaux C, D\u2019Souza W, et al. Effectiveness and tolerability of 12-month brivaracetam in the real world: EXPERIENCE, an international pooled analysis of individual patient records. CNS Drugs. 2023;37:819\u201335.","journal-title":"CNS Drugs"},{"key":"580_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fneur.2018.00038","volume":"9","author":"F Zahnert","year":"2018","unstructured":"Zahnert F, Krause K, Immisch I, et al. Brivaracetam in the treatment of patients with epilepsy-first clinical experiences. Front Neurol. 2018;9:38.","journal-title":"Front Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00580-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00580-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00580-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T15:25:56Z","timestamp":1710861956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00580-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00580-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Simona Lattanzi has received speaker\u2019s or consultancy fees from Angelini Pharma, Eisai, GW Pharmaceuticals, Medscape, and UCB Pharma and has served on advisory boards for Angelini Pharma, Arvelle Therapeutics, BIAL, Eisai, GW Pharmaceuticals, and Rapport Therapeutics outside the submitted work. Daniela Audenino\u00a0has received speaker or consultancy fees from Angelini Pharma and UCB\u00a0Pharma outside the submitted work. Paolo Bonanni has received speaker\u2019s or consultancy fees from EISAI, Angelini, Jazz and Livanova and has served on advisory boards for BIAL, Eisai, Proveca outside the submitted work. Filippo Dainese has received speaker or consultancy fees from Angelini Pharma, Eisai and UCB Pharma outside the submitted work. Valentina Chiesa has received speaker and advisory board honoraria from Angelini Pharma, Eisai Pharma, GW, UCB Pharma outside the submitted work. Filippo Dainese has received speaker or consultancy fees from Angelini Pharma, Eisai and UCB Pharma outside the submitted work. Marta Piccioli has received speaker\u2019s or consultancy fees from Angelini, EISAI, and UCB Pharma outside the submitted work. Nicoletta Foschi, Chiara Martellino, Giovanni Boero, Edoardo Ferlazzo, Alessandra Ferrari, and Angelo Labate have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the ethical committee of the Marche Polytechnic University, Ancona, Italy (ID CERM 176) and conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from each patient or the legal representative for the collection and analysis of data and the dissemination of the results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}